Oxford Biomedica Raises £60 Million for US Expansion
- Ben Jones
- Aug 15
- 2 min read
Gene therapy company strengthens transatlantic presence with strategic funding round
Oxford Biomedica has successfully completed a £60 million fundraising through share placing and subscription to accelerate expansion of its US operations, the gene and cell therapy specialist announced today.
The company, which develops advanced viral vector manufacturing for gene therapies, plans to use the proceeds to bolster its manufacturing capacity in the United States and support growing client demand. The funding round represents a significant vote of confidence in Oxford Biomedica’s technological capabilities and market positioning.
The capital injection comes at a crucial time for the biotech sector, with increased demand for gene therapy manufacturing services across global markets. Oxford Biomedica’s proprietary LentiVector platform has established the company as a leading provider of manufacturing solutions for gene therapy developers.
Chief Executive Stuart Henderson highlighted the strategic importance of US market expansion, noting strong demand from American pharmaceutical companies for the company’s manufacturing expertise. The additional capacity will enable Oxford Biomedica to serve larger contracts and reduce delivery timelines for clients.
The gene therapy market has experienced substantial growth, with regulatory approvals increasing globally and pharmaceutical companies investing heavily in next-generation treatments. Oxford Biomedica’s timing aligns with this expansion, positioning the company to capture increased market share.
Analysts welcomed the funding announcement, noting Oxford Biomedica’s strong track record in viral vector manufacturing and established client relationships with major pharmaceutical companies. The additional US capacity should enable the company to compete more effectively for large-scale manufacturing contracts.
The biotech sector faces ongoing challenges including regulatory complexity and high development costs, but gene therapy represents one of the fastest-growing segments. Oxford Biomedica’s focus on manufacturing services rather than drug development provides a more stable revenue model compared to traditional biotech companies.
The share placing was conducted at market rates, indicating strong institutional investor support for the company’s expansion strategy. This funding round follows previous successful capital raises and demonstrates continued confidence in Oxford Biomedica’s growth prospects.
